Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 24;13(3):52.
doi: 10.3390/ph13030052.

4-Amino-1,2,4-triazole-3-thione as a Promising Scaffold for the Inhibition of Serine and Metallo- β-Lactamases

Affiliations

4-Amino-1,2,4-triazole-3-thione as a Promising Scaffold for the Inhibition of Serine and Metallo- β-Lactamases

Pasquale Linciano et al. Pharmaceuticals (Basel). .

Abstract

The emergence of bacteria that co-express serine- and metallo- carbapenemases is a threat to the efficacy of the available β-lactam antibiotic armamentarium. The 4-amino-1,2,4-triazole-3-thione scaffold has been selected as the starting chemical moiety in the design of a small library of β-Lactamase inhibitors (BLIs) with extended activity profiles. The synthesised compounds have been validated in vitro against class A serine β-Lactamase (SBLs) KPC-2 and class B1 metallo β-Lactamases (MBLs) VIM-1 and IMP-1. Of the synthesised derivatives, four compounds showed cross-class micromolar inhibition potency and therefore underwent in silico analyses to elucidate their binding mode within the catalytic pockets of serine- and metallo-BLs. Moreover, several members of the synthesised library have been evaluated, in combination with meropenem (MEM), against clinical strains that overexpress BLs for their ability to synergise carbapenems.

Keywords: 4-amino-1,2,4-triazole-3-thione; bacterial resistance; broad-spectrum activity; non-covalent inhibition; structure-based drug design; thione/thiol tautomerism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Scheme 1
Scheme 1
Reagents and conditions: (a) CS2, H2O, refl., 3h, 50% yield; (b) formic acid (1 mL per gram of 4), refl., 45 min, 87% yield; (c) aryl carboxaldehyde (1.1 eq.), 35% HCl (cat.), EtOH, refl., 4–12h, yield: 76% (for 2a), 85% (for 2b), 67% (for 2c), 62% (for 2d), 87% (for 2e), 79% (for 2f), 70% (for 2g); (d) NaBH4 (8 eq.), 80% EtOH (v/v), 0 °C to r.t. 6–24h, yield: 90% (for 1a), 87% (for 1b), 75% (for 1c), 83% (for 1d), 75% (for 1e), 87% (for 1f), 81% (for 1g).
Figure 1
Figure 1
Docking pose of the compounds in VIM-1, IMP-1 and KPC-2. (ad) Compounds 1d, 1f, 2b and 2g in VIM-1 binding site, respectively. (eh) Compounds 1d, 1f, 2b and 2g in IMP-1 binding site, respectively. (il) Compounds 1d, 1f, 2b and 2g in KPC-2 binding site, respectively. The position originally occupied by the catalytic water wat1 in KPC-2 has been indicated. Even when the water was not retained in the docking simulations, none of the compounds occupied its position, nor was it able to generate valuable contact with it. Proteins are displayed as cartoon (VIM-1, magenta; IMP-1, light blue; KPC-2 dark yellow), zinc atoms are solid grey spheres and their coordination bonds are represented as grey dashed lines. The side chains of the relevant residues are shown as sticks and are labelled accordingly; ligands are depicted in thick, bright-coloured sticks. Hydrogen bonds formed by the ligand with the residues lining the pocket are shown as yellow dashed lines. The catalytic water in KPC-2 is labelled and shown as a red sphere. For clarity, residues have been numbered according to the PDB.

References

    1. World Health Organization . Antimicrobial Resistance: Global Report on Surveillance. WHO; Geneva, Switzerland: 2016. WHO Librrary Catalog Data.
    1. Culyba M.J., Mo C.Y., Kohli R.M. Targets for Combating the Evolution of Acquired Antibiotic Resistance. Biochemistry. 2015;54:3573–3582. doi: 10.1021/acs.biochem.5b00109. - DOI - PMC - PubMed
    1. Bellio P., Di L., Mancini A., Piovano M., Nicoletti M., Brisdelli F., Tondi D., Cendron L., Franceschini N., Amicosante G., et al. Phytomedicine Original article SOS response in bacteria: Inhibitory activity of lichen secondary metabolites against Escherichia coli RecA protein. Phytomedicine. 2017;29:11–18. doi: 10.1016/j.phymed.2017.04.001. - DOI - PubMed
    1. D’Angelo F., Baldelli V., Halliday N., Pantalone P., Polticelli F., Fiscarelli E., Williams P., Visca P., Leoni L., Rampioni G. Identification of FDA-Approved Drugs as Antivirulence Agents Targeting the pqs Quorum-Sensing System of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2018;62:e01296-18. doi: 10.1128/AAC.01296-18. - DOI - PMC - PubMed
    1. Mobarki N., Almerabi B., Hattan A. Antibiotic Resistance Crisis. Int. J. Med. Dev. Ctries. 2019;40:561–564. doi: 10.24911/IJMDC.51-1549060699. - DOI